

Matthew M Gubin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1169595/publications.pdf>

Version: 2024-02-01

20
papers

7,498
citations

471509

17
h-index

713466

21
g-index

21
all docs

21
docs citations

21
times ranked

14049
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. <i>Cell</i> , 2015, 162, 1229-1241.	28.9	2,158
2	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014, 515, 577-581.	27.8	1,705
3	New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. <i>Current Opinion in Immunology</i> , 2014, 27, 16-25.	5.5	1,163
4	MHC-II neoantigens shape tumour immunity and response to immunotherapy. <i>Nature</i> , 2019, 574, 696-701.	27.8	563
5	Tumor neoantigens: building a framework for personalized cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2015, 125, 3413-3421.	8.2	502
6	TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. <i>Cell</i> , 2020, 182, 886-900.e17.	28.9	309
7	High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. <i>Cell</i> , 2018, 175, 1014-1030.e19.	28.9	292
8	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <i>Cancer Immunology Research</i> , 2017, 5, 106-117.	3.4	236
9	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , 2016, 130, 25-74.	2.2	181
10	The odds of immunotherapy success. <i>Science</i> , 2015, 350, 158-159.	12.6	87
11	Posttranscriptional Gene Regulation of IL-17 by the RNA-Binding Protein HuR Is Required for Initiation of Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2013, 191, 5441-5450.	0.8	65
12	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. <i>Science Immunology</i> , 2022, 7, .	11.9	52
13	Coordinate Regulation of <i>GATA-3</i> and Th2 Cytokine Gene Expression by the RNA-Binding Protein HuR. <i>Journal of Immunology</i> , 2011, 187, 441-449.	0.8	45
14	Cancer Immunoediting in the Era of Immuno-oncology. <i>Clinical Cancer Research</i> , 2022, 28, 3917-3928.	7.0	31
15	Conditional Knockout of the RNA-Binding Protein HuR in CD4+ T Cells Reveals a Gene Dosage Effect on Cytokine Production. <i>Molecular Medicine</i> , 2014, 20, 93-108.	4.4	29
16	Incisional hernia recurrence through genomic profiling: a pilot study. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2013, 17, 193-202.	2.0	27
17	The RNA-Binding Protein HuR Posttranscriptionally Regulates IL-2 Homeostasis and CD4+ Th2 Differentiation. <i>ImmunoHorizons</i> , 2017, 1, 109-123.	1.8	20
18	BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. <i>Cancer Immunology Research</i> , 2022, 10, 597-611.	3.4	16

#	ARTICLE	IF	CITATIONS
19	Transcriptomic-Wide Discovery of Direct and Indirect HuR RNA Targets in Activated CD4+ T Cells. PLoS ONE, 2015, 10, e0129321.	2.5	13
20	The dynamics of an immunotherapy duo. Nature Cancer, 2022, 3, 376-378.	13.2	2